Why is Concord Biotech falling/rising?

As of 23-Jun, Concord Biotech Ltd's stock price is currently at 1,822.50, reflecting a decrease of 17.55 points or 0.95%. The stock has been underperforming recently, having fallen consecutively for the last six days, resulting in a total decline of 14.04% during this period. It opened today with a loss of 2.45% and reached an intraday low of Rs 1,777.75, which is a drop of 3.39%. Over the past week, the stock has seen a significant decline of 12.98%, while its performance over the last month shows a positive return of 18.27%. Despite the recent downturn, the company has demonstrated strong long-term fundamentals, with an average Return on Equity (ROE) of 20.62% and healthy growth in operating profit. Additionally, institutional investors have increased their stake, indicating confidence in the company's potential.
Broader market context shows that while Concord Biotech has struggled in the short term, it has outperformed the broader market over the past year, generating a return of 16.88% compared to the BSE 500's 2.78%. The stock's recent performance contrasts with the benchmark's slight gain of 0.12% over the past week. This divergence suggests that the stock's current decline may be influenced by specific company-related factors rather than broader market trends. The increased participation from institutional investors may provide some support, but the stock's recent negative momentum and underperformance against its sector indicate challenges that could be affecting investor sentiment.